Ya-Ting Yang

Ya-Ting Yang

Auto-generated profile, based on publicly available information

Ya-Ting Yang

Department of Neurology, Killion Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
AHAshley S. Harms
Ashley S. Harms
YYYa-Ting Yang
Ya-Ting Yang
MTMariadeLourdes Tansey
MariadeLourdes Tansey
Parkinson’s disease (PD) is a multisystem disorder with characteristics of a chronic inflammatory disease. To develop effective immunomodulatory interventions to combat PD, we need to think innovatively about the implications of orchestrated central and peripheral innate and adaptive immune responses that occur as the disease begins and progresses.

26 March 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Lixin WanLixin Wan
Lixin Wan
YWYang Wang
Yang Wang
ZZZijie Zhang
Zijie Zhang
JWJiaxin Wang
Jiaxin Wang
MNMenglan Niu
Menglan Niu
DBDengke Bao
Dengke Bao
TEFM (transcription elongation factor of mitochondria) has been identified as a novel nuclear-encoded transcription elongation factor in the transcription of mitochondrial genome. Our bioinformatics analysis of TCGA data revealed an aberrant over-expression of TEFM in hepatocellular carcinoma (HCC). We analyzed its biological effects and clinical significance in this malignancy. TEFM expression was analyzed by quantitative real-time PCR, western blot, and immunohistochemistry analysis in HCC tissues and cell lines. The effects of TEFM on HCC cell growth and metastasis were determined by cell proliferation, colony formation, flow cytometric cell cycle and apoptosis, migration, and invasion assays. TEFM expression was significantly increased in HCC tissues mainly caused by down-regulation of miR-194-5p. Its increased expression is correlated with poor prognosis of HCC patients. TEFM promoted HCC growth and metastasis both in vitro and in vivo by promoting G1–S cell transition, epithelial-to-mesenchymal transition (EMT), and suppressing cell apoptosis. Mechanistically, TEFM exerts its tumor growth and metastasis promoting effects at least partly through increasing ROS production and subsequently by activation of ERK signaling. Our study suggests that TEFM functions as a vital oncogene in promoting growth and metastasis in HCC and may contribute to the targeted therapy of HCC.

1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GNGeorgy Y. Nadysev
Georgy Y. Nadysev
ATAlexander S. Tikhomirov
Alexander S. Tikhomirov
MLMing-Hung Lin
Ming-Hung Lin
YYYa-Ting Yang
Ya-Ting Yang
LDLyubov G. Dezhenkova
Lyubov G. Dezhenkova
Pin Ju ChuehPin Ju Chueh
Pin Ju Chueh

13 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJhodi M. Webster
Jhodi M. Webster
YYYa-Ting Yang
Ya-Ting Yang
AMAidan T. Miller
Aidan T. Miller
AZAsta Zane
Asta Zane
KSKasandra Scholz
Kasandra Scholz
JMJeremy Molina
Jeremy Molina
Alzheimer’s (AD) and Parkinson disease (PD) pathology often co-occur. Amyloid-β and phosphorylated tau are found in 30-50% of idiopathic PD cases, while α-synuclein inclusions are present in 50% of AD cases. These co-pathologies are linked to increased mortality and earlier onset of cognitive decline. Immune activation is a hallmark of these neurodegenerative diseases, but current models primarily examine each pathology in isolation. How these co-pathologies drive inflammation and neuronal loss remains poorly understood. We therefore developed a mouse model combining tau, amyloid-β, and α-synuclein. We found that co-pathologies synergistically trigger an amplified neuroimmune response, with expanded populations of CD4 + and CD8 + tissue-resident memory T cells and CD68 + microglia, compared to single pathologies. These changes were abundant in the hippocampus and cortex, regions with elevated protein pathology load and enhanced neuronal loss. Our findings demonstrate that co-pathologies enhance proteinopathy and synergistically enhance immune activation and neurodegeneration, suggesting that combinatorial therapeutic strategies that target both co-pathologies and inflammation, may be disease modifying. Summary: Webster et al. demonstrate that co-occurring Alzheimer’s and Parkinson disease protein pathologies, common in cognitively impaired patient populations, amplify proteinopathy and synergistically enhance CNS neuroinflammatory responses and neurodegeneration. This work supports the need for combinatorial therapeutic strategies and positions neuroinflammation as an important link for co-pathology enhanced neurodegeneration.

30 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YYYa-Ting Yang
Ya-Ting Yang
YGYves Greatti
Yves Greatti
AMAidan T. Miller
Aidan T. Miller
JWJhodi M. Webster
Jhodi M. Webster
AJAsta Jurkuvenaite
Asta Jurkuvenaite
AHAshley S. Harms
Ashley S. Harms
Microglial activation in response to aggregated α -synuclein ( α -syn) accumulation is a pathological hallmark of Parkinson’s disease (PD). A distinct activated microglial state, disease-associated microglia (DAM), has been identified across multiple neurodegenerative disorders, including PD. However, the transcriptional and epigenetic programs governing DAM differentiation remain unclear. Here, we show that neuronal α -syn overexpression drives progressive microglial state transitions toward DAM, accompanied by increased phagocytic activity and enhanced cytokine and chemokine production. Integrative transcriptomic and chromatin accessibility analyses reveal a hierarchical NF-κB–AP-1–IRF regulatory program underlying these state transitions. Microglial NF-κB p65 (RelA) or IRF4 deficiency impairs microglial progression toward DAM, with RelA and IRF4 governing early microglial activation and subsequent DAM differentiation, respectively. Enrichment of NF-κB, AP-1, and IRF motifs in DAM in human PD supports conservation of this regulatory program across species. Together, our findings establish RelA and IRF4 as sequential, stage-specific regulators that coordinate α -syn-induced DAM differentiation in PD.